Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group
about
Current Management of Childhood Acute Myeloid Leukemia.Strategies for reducing the treatment-related physical burden of childhood acute myeloid leukaemia - a review.Algorithm for analysis of administrative pediatric cancer hospitalization data according to indication for admission.Concordance of copy number alterations using a common analytic pipeline for genome-wide analysis of Illumina and Affymetrix genotyping data: a report from the Children's Oncology Group.Shorter Remission Telomere Length Predicts Delayed Neutrophil Recovery After Acute Myeloid Leukemia Therapy: A Report From the Children's Oncology Group.Feasibility, efficacy, and adverse effects of outpatient antibacterial prophylaxis in children with acute myeloid leukemia.First do no harm: infectious deaths in pediatric ALL.Thrombosis as a complication of central venous access in pediatric patients with malignancies: a 5-year single-center experience.Postinduction Supportive Care of Pediatric Acute Myelocytic Leukemia: Should Patients be Kept in the Hospital?Protocol for a systematic review of reductions in therapy for children with low-risk febrile neutropenia.A comparison of resource utilization following chemotherapy for acute myeloid leukemia in children discharged versus children that remain hospitalized during neutropenia.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.A comparison of discharge strategies after chemotherapy completion in pediatric patients with acute myeloid leukemia: a report from the Children's Oncology Group.How Well Do All Patient Refined-Diagnosis-Related Groups Explain Costs of Pediatric Cancer Chemotherapy Admissions in the United States?Antibiotic prophylaxis with teicoplanin on alternate days reduces rate of viridans sepsis and febrile neutropenia in pediatric patients with acute myeloid leukemia.Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia.Preventive antibiotics in pediatric patients with acute myeloid leukemia (AML).Current variations in childhood cancer supportive care in the Netherlands.Systematic review of reduced therapy regimens for children with low risk febrile neutropenia.Bending the Cost Curve in Childhood Cancer.Treatment-related adverse events associated with a modified UK ALLR3 induction chemotherapy backbone for childhood relapsed/refractory acute lymphoblastic leukemia.Acute Myeloid Leukemia: How Do We Measure Success?How I manage children with neutropenia.Lack of Effectiveness of Neutropenic Diet and Social Restrictions as Anti-Infective Measures in Children With Acute Myeloid Leukemia: An Analysis of the AML-BFM 2004 Trial.Clinical Characteristics of Bloodstream Infections in Pediatric Acute Leukemia: A Single-center Experience with 231 Patients.High infection-related mortality in pediatric acute myeloid leukemia without preventive antibiotics and antifungals. Retrospective cohort study of a single center from a middle-income country.Risk factors for and prevention of bloodstream infection in pediatric AML-The debate continues.Risk factors for bacteremia and central line-associated blood stream infections in children with acute myelogenous leukemia: A single-institution report.Earlier initiation of antibiotic therapy: Does prophylaxis offer greater benefit in AML?Development of clinical practice guidelines for supportive care in childhood cancer--prioritization of topics using a Delphi approach.Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.Meta-ethnography of experiences of early discharge, with a focus on paediatric febrile neutropenia.Identifying patient- and family-centered outcomes relevant to inpatient versus at-home management of neutropenia in children with acute myeloid leukemia.Combination of clofarabine, cyclophosphamide, and etoposide for relapsed or refractory childhood and adolescent acute myeloid leukemia.Adverse effects of intravenous vancomycin-based prophylaxis during therapy for pediatric acute myeloid leukemia.Treatment-related mortality in newly diagnosed pediatric cancer: a population-based analysis.Editorial commentary: Clostridium difficile in pediatric oncology patients: more questions than answers.Quest for certainty regarding early discharge in paediatric low-risk febrile neutropenia: a multicentre qualitative focus group discussion study involving patients, parents and healthcare professionals in the UK.
P2860
Q30244036-BDA6830F-698A-4CD1-8AB3-415173C84CBCQ30244244-06028537-FB48-4066-A0B9-580185E3F0C6Q30856931-18761163-6FE2-4DE1-9EBD-EB043217A32BQ30979681-B889E0A7-56CA-48FF-802B-17A20B7DE52CQ33732434-3917DB5C-58D9-4921-8CAB-077822D4CB05Q33779342-4799F38D-9228-41C0-A0CF-FB3CF7ACF01BQ34047922-25136719-DD51-4219-8178-A4D6D78ED6C0Q34333047-FAC958E4-57A8-490A-8BF5-40979C94E781Q34346926-1AF73902-D951-4155-B9AA-8F72F7C46E2AQ34525767-866D441C-B487-4C12-A6BE-3186C862A4D4Q36051777-24F28C1A-355B-401B-830E-9FD3FB1F31F3Q36053792-844CBC14-49A0-4F5F-A1C2-1F3A5F7D92F5Q36984687-E06BF379-60CA-48C8-A740-55A5AE756F20Q37240926-5A88D3F0-604B-4657-9F7F-166D99495A1DQ37579563-787E2B89-B9FC-4663-AB0C-C67BF968142AQ38264086-DE6C7469-54D0-4B6D-9379-7E413109C2DDQ38366487-D9C93385-B6F0-4BBC-91A5-809274E69135Q38640416-A69F876A-7A97-4819-98DA-B8A4FD51AFCEQ38693662-660B004C-A6CA-4244-9B73-E4668A2B7237Q38837762-E2A5D611-551F-4E39-ADD5-78C22A39C9C3Q38839812-C8A66A08-783D-48FD-9D8C-59FBDDB5E313Q38948650-76C4CE19-6210-4360-B995-83470BDF12F4Q39248493-DCE8DC26-6BD1-4012-A038-4988643D7CB6Q39704919-9FE16C48-CF98-458A-83E2-6FBB31D91651Q40042111-9622702C-80BF-4666-A3FC-12E5C3929A3FQ40274721-065C3820-6008-486C-A0A9-5F1E7BBD394FQ40482328-287D2A80-9791-4A3E-B63F-00E41112F645Q40544089-4DA38DBD-1C27-416C-8702-073F4ABB72E7Q41385125-BA928F5C-363C-4CCB-8994-357B41D6C6BBQ41595378-9BCBA529-3E4C-4BD9-84DD-E572770DD63EQ41987065-EB1E9A2A-5C32-4303-BA21-2661015C21FEQ46169481-1212D42D-31C1-4CA2-8123-A19DA649F191Q47568443-10CFA920-AD61-418E-AF2C-C90D6CC73FBCQ47650171-E184EC2D-4DF1-4D56-A17F-2F768C8626B4Q48175362-82DBAB38-0314-466E-8561-C0BA5B596B07Q49921680-5BABC0AD-1351-42E7-A242-13DD4E4510D2Q50422207-92F48C36-9BD2-439F-8928-AC86394AAEDEQ53876424-4849796E-0C58-488C-B35B-B7674BD80C75Q55043679-12552463-8175-4D3D-9989-F60B5BF39490
P2860
Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children's Oncology Group
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Effectiveness of supportive ca ...... the Children's Oncology Group
@ast
Effectiveness of supportive ca ...... the Children's Oncology Group
@en
type
label
Effectiveness of supportive ca ...... the Children's Oncology Group
@ast
Effectiveness of supportive ca ...... the Children's Oncology Group
@en
prefLabel
Effectiveness of supportive ca ...... the Children's Oncology Group
@ast
Effectiveness of supportive ca ...... the Children's Oncology Group
@en
P2093
P2860
P1433
P1476
Effectiveness of supportive ca ...... the Children's Oncology Group
@en
P2093
Alan S Gamis
Lillian Sung
Richard Aplenc
Robert B Gerbing
Thomas Lehrnbecher
Todd A Alonzo
P2860
P304
P356
10.1182/BLOOD-2013-01-476614
P407
P577
2013-03-07T00:00:00Z